Moxonidin Stada (Moxonidine)

Moxonidine, the active ingredient in Moxonidin Stada, is an imidazoline receptor agonist presented as a tablet for oral use. It selectively stimulates central I1 imidazoline receptors, leading to reduced sympathetic outflow and consequent lowering of elevated blood pressure in adult patients diagnosed with primary hypertension.

GNH USA supplies Moxonidin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable global distribution. The company adheres to stringent regulatory standards and provides comprehensive documentation for regulatory submissions.

Moxonidine is used in the management of hypertension, acting on central sympathetic pathways to achieve blood‑pressure control. - Hypertension: reduces systolic and diastolic blood pressure in patients with primary (essential) hypertension. - Resistant hypertension: provides additional blood‑pressure reduction when standard antihypertensive regimens are insufficient. - Hypertensive patients with metabolic syndrome: helps lower blood pressure while having a neutral effect on metabolic parameters.

Moxonidine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially upon standing. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally low heart rate. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Moxonidine, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Renal impairment: adjust dose or use with caution in patients with reduced kidney function. - Hepatic impairment: consider dose reduction in those with liver disease. - Concomitant depression: monitor mood as central sympatholytic agents may affect CNS. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Moxonidine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other centrally acting antihypertensives: additive hypotensive effect may cause severe blood pressure drop. - Beta‑blockers: combined use can lead to pronounced bradycardia. - Potassium‑sparing diuretics: risk of hyperkalaemia when used together.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate the antihypertensive response of Moxonidine. - Diuretics: concurrent use can increase electrolyte disturbances. - Alcohol: can enhance sedative and hypotensive effects.